Topiramate-Induced Depression
Publication: American Journal of Psychiatry
To the Editor: Topiramate, an antiepileptic medication, is often used as an adjunctive mood stabilizer for patients with bipolar disorder (1). Potential weight loss makes this medication appealing; however, depression is another reported side effect (2). We report on three patients with bipolar disorder in which topiramate may have exacerbated depression. Topiramate was prescribed in lieu of higher doses of the patients’ current mood stabilizers because of concerns about weight gain.
Ms. A, a 24-year-old woman, was seen with irritability and mild depression. She was currently taking gabapentin and zolpidem. Treatment with topiramate was initiated at 25 mg/day and titrated to 50 mg/day. After 2 days at the higher dose, Ms. A reported severe depression and suicidal ideation. Topiramate was promptly discontinued; 1 week later Ms. A no longer felt hopeless or suicidal.Ms. B, a 40-year-old woman, reported racing thoughts but no depressive symptoms; her current medications were valproic acid, risperidone, and cetirizine. Treatment with topiramate was titrated to 50 mg/day over 1 week. One week later Ms. B reported severe depression with anergia and anhedonia. Decreasing her dose of topiramate stepwise over 2 days relieved her depressive symptoms.Ms. C, a 34-year-old woman taking fluoxetine, thyroxine, and valproic acid, was seen with irritability, racing thoughts, psychomotor agitation, and anxiety. Topiramate therapy was initiated, and the dose was titrated over 1 week to 50 mg/day. Two weeks later Ms. C called to report severe depression, vague suicidal ideation, and anhedonia. Her dose of topiramate was decreased to 25 mg/day and discontinued 3 days later. Three days after discontinuation Ms. C reported not being depressed.
We report on these patients to highlight a possible relationship between topiramate and substantial depression in patients with bipolar disorder. Symptoms of depression began or increased within 1 week of topiramate treatment or with titration to 50 mg/day. Each of the patients experienced significant relief from depression 1 to 2 weeks after discontinuation of topiramate. The close association with onset of the most severe depression these patients had ever experienced is notable. However, although no new medications had been initiated in the previous 3 months in any of these cases, all of the patients had a diagnosis of bipolar disorder, so the onset of depression could have been coincidental. Their depression may also have been due to a synergistic interaction between topiramate and their other medications. These symptoms of depression correlate with the neurology literature (2, 3), in which psychiatric disorders are noted to occur with topiramate therapy. Although topiramate has been shown to be effective in mood stabilization, physicians prescribing it should be aware that serious depression might be an adverse effect. This observation merits further research.
References
1.
McElroy SL, Suppes T, Keck PE, Frye MA, Denicoff KL, Altshuler LL, Brown ES, Nolen WA, Kupka RW, Rochussen J, Leverich GS, Post RM: Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol Psychiatry 2000; 47:1025-1033
2.
Martin R, Kuzniecky R, Ho S, Hetherington H, Pan J, Sinclair K, Gilliam F, Faught E: Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology 1999; 52:321-327
3.
Kellet MW, Smith DF, Stockton PA, Chadwick DW: Topiramate in clinical practice: first year’s postlicensing experience in a specialist epilepsy clinic. J Neurol Neurosurg Psychiatry 1999; 66:759-763
Information & Authors
Information
Published In
History
Published online: 1 October 2001
Published in print: October 2001
Authors
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
There are no citations for this item
View Options
View options
PDF/ePub
View PDF/ePubGet Access
Login options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).